Clinical Trials
1,972 trialsNCT04070209 2026-05-27
Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)
Sir Mortimer B. Davis - Jewish General Hospital
Phase 2 Active not recruiting
NCT04126070 2026-05-27
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT07608718 2026-05-27
Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT03570827 2026-05-26
Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy
Mayo Clinic
Phase 2 Completed
NCT03934840 2026-05-26
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT05496959 2026-05-26
LUNAR
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT07475403 2026-05-26
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT02316548 2026-05-22
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
NRG Oncology
Phase 2 Terminated
NCT02710734 2026-05-22
Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN)
Fox Chase Cancer Center
Phase 2 Completed
NCT03324282 2026-05-22
GCISAVE
University Hospital, Bordeaux
Phase 2 Terminated
NCT04007770 2026-05-22
Acupuncture Pilot Study for Cancer-related Cognitive Function
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05263050 2026-05-22
Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
Fox Chase Cancer Center
Phase 2 Recruiting
NCT07023432 2026-05-22
Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07602101 2026-05-22
Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma
RenJi Hospital
Phase 2 Not yet recruiting
NCT01885949 2026-05-20
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT04879940 2026-05-20
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06053658 2026-05-20
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07593040 2026-05-20
Moonlanding
Vall d'Hebron Institute of Oncology
Phase 2 Not yet recruiting
NCT03606837 2026-05-19
PROSTATEP
University Hospital, Bordeaux
Phase 2 Completed
NCT04346225 2026-05-19
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
University of California, San Francisco
Phase 2 Recruiting
NCT06035224 2026-05-19
Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma
RenJi Hospital
Phase 2 Active not recruiting
NCT03933670 2026-05-18
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
University of California, San Francisco
Phase 2 Recruiting
NCT05751434 2026-05-18
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT06863311 2026-05-18
EXACT
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07285044 2026-05-18
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Phase 2 Recruiting
NCT07592910 2026-05-18
MOMENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Not yet recruiting
NCT07593079 2026-05-18
Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT00183937 2026-05-15
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer
University of Southern California
Phase 2 Terminated
NCT00544830 2026-05-15
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04019964 2026-05-15
Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04565496 2026-05-15
PEM-PRO
IRCCS San Raffaele
Phase 2 Withdrawn
NCT04716725 2026-05-15
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT04947254 2026-05-15
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05730712 2026-05-15
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT06940518 2026-05-15
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT07476001 2026-05-15
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT02312557 2026-05-14
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03604757 2026-05-14
UROPET
University Hospital, Bordeaux
Phase 2 Completed
NCT04030559 2026-05-14
Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects
University of California, Davis
Phase 2 Terminated
NCT05168618 2026-05-14
AtezoCab
University of Utah
Phase 2 Recruiting
NCT06591650 2026-05-14
GCND
Fudan University
Phase 2 Recruiting
NCT06708949 2026-05-14
A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05169970 2026-05-13
A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05239624 2026-05-13
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT07455903 2026-05-13
Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT
Baptist Health South Florida
Phase 2 Recruiting
NCT03047135 2026-05-12
Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker Analysis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Active not recruiting
NCT04731844 2026-05-12
Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
University of Rochester
Phase 2 Completed
NCT05868265 2026-05-12
A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06852638 2026-05-12
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
Phase 2 Recruiting
NCT03601455 2026-05-11
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting